FMP
XETRA
46.6 EUR
0.25 (0.536%)
Dr. Stefan Glombitza
Healthcare
Biotechnology
https://www.formycon.com
XETRA
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also develo...
N/A
DE000A1EWVY8
N/A
Fraunhoferstrasse 15
49 89 864 667 100
DE
224
Jan 4, 2011
-
XETRA
Biotechnology
Healthcare
-
DE000A1EWVY8
DE
46.6
0.84
8.08k
822.81M
-
44.4-81.1
-17.39
-
-
-
-
-12.33
-
https://www.formycon.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.